Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AGN-242428 and AGN-231868 in Dry Eye Disease
NCT04030962Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vimirogant, AGN-231868 in dry eye disease (DED), sponsored by AbbVie Inc.. Started Mar 2020; status: completed.
02
Drugs
vimirogantAGN-231868
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04030962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030962.